Becton, Dickinson and Company (BDX) investor relations material

Portfolio transformation and growth platforms

• Recent portfolio exits and the separation of the life science business have sharpened focus, with the Waters transaction valued at about $20 billion and 20x multiples.

• Growth platforms such as biologics, urinary incontinence, tissue regeneration, pharmacy automation, and peripheral vascular are delivering high single- to double-digit growth and stronger margins.

• The Excellence Unleashed strategy is driving improvements across commercial, innovation, and operational agendas, contributing to sequential strong quarters.

• 90% of the portfolio is growing at high single digits, with targeted efforts underway to address the remaining 10%.

• Analyst Day on December 10 will unveil a new long-range plan (LRP), updated revenue, margin, and cash flow outlooks, and new innovations.

Financial outlook and headwinds

• Fiscal Q4 growth is expected to decelerate due to Alaris-related headwinds, with 200 basis points of pressure anticipated in both Q4 and FY 2027.

• Margin ramp in Q4 is supported by favorable product mix, BD Excellence operational efficiencies, and mitigation of tariff impacts.

• Three main headwinds—Alaris, vaccines, and China—are expected to lessen over time, with Alaris and vaccines showing clearer paths to improvement, while China remains uncertain due to ongoing value-based procurement (VBP) pressures.

• Pricing discipline is expected to continue, with more positive price realization in 2027 as China becomes a smaller part of the business.

• Modest EPS leverage is anticipated for FY 2027, with formal guidance to be provided in November.

Product and innovation highlights

• Alaris is gaining significant market share, with expectations for continued strong performance and positive pull-through from higher-margin sets.

• Pharm Systems is expected to return to high single-digit growth long term, with vaccines becoming a neutral factor and biologics and GLP-1s driving strong double-digit growth.

• Growth drivers include Advanced Patient Monitoring (APM), PureWick, and regenerative medicine, all benefiting from increased investment and innovation.

• PureWick is on track to reach $1 billion by 2030, with new product launches and expanded reimbursement channels.

• Regenerative medicine is expanding into new indications and geographies, leveraging proprietary biomaterials and clinical data.